Sign up
Quantellect · Congress · Issuer Profile
NYSE: NVSNovartis AG ADR
HealthcareMkt Cap $303.67BCongress ownership rank #150

Novartis AG ADR Congressional Trading

According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 168 trades in Novartis AG ADR (NYSE: NVS) since 2014, across 32 members, worth an estimated $5.4M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 85 buys against 82 sells, a modestly buy-led skew, with Democratic members responsible for 33% of the trades and Republican members 67%. The most recent disclosure shown was filed September 2026, and Alan Armstrong has filed the most NVS transactions among those shown, with 2. Other recent filers include Kevin Hern and Rohit Khanna. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Novartis AG ADR's current Quantellect Tide Score is 71 out of 100 (High Tide), Top 7% of universe (3865); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Novartis AG ADR (NVS) stock overview and the complete trade table below.

Data updated

Trades
5
Politicians
3
Filings
4
Disclosed Vol
$89.00K
Buys
2
40%
Sells
3
60%

Price & congressional trade timeline

Party breakdown

Novartis AG ADR congressional trading activity

PoliticianPublishedTradedFiled AfterTypeSizeReturnOwner
Sep 25, 2026Aug 27, 202629 daysSell
$15,001 - $50,000
+0.36%Self
Jul 21, 2026Mar 31, 2026112 daysBuy
$1,001 - $15,000
+1.61%Self
Jul 21, 2026Mar 30, 2026113 daysBuy
$15,001 - $50,000
+3.23%Self
Apr 7, 2026Mar 13, 202625 daysSell
$1,001 - $15,000
+1.15%Spouse
Mar 9, 2026Feb 13, 202624 daysSell
$1,001 - $15,000
-1.94%Spouse
Go to

Novartis AG ADR (NVS) congressional trading FAQ

Can members of Congress legally trade Novartis AG ADR (NVS) stock?

Yes. Members of Congress are permitted to trade individual stocks, including Novartis AG ADR (NVS), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.

Are congressional Novartis AG ADR (NVS) trades public?

Yes. Every congressional trade in Novartis AG ADR (NVS) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.

How many times has Congress traded Novartis AG ADR (NVS)?

Members of Congress have disclosed 168 trades in Novartis AG ADR (NVS) worth $5.4M across 32 members, according to public STOCK Act filings.

Which members of Congress have traded Novartis AG ADR (NVS)?

Recent and active filers of Novartis AG ADR (NVS) disclosures include Alan Armstrong, Rohit Khanna, Kevin Hern. The full member-by-member trade list is on this page.

Do Democrats or Republicans trade Novartis AG ADR (NVS) more?

Across disclosed Novartis AG ADR (NVS) trades, 33% were by Democrats and 67% by Republicans, led by Republicans (67%).

What is the most recent congressional Novartis AG ADR (NVS) trade?

The most recent disclosed Novartis AG ADR (NVS) filing reported a sell by Kevin Hern, filed Sep 24, 2026.

What is Novartis AG ADR (NVS)'s Tide Score?

Novartis AG ADR (NVS) has a Quantellect Tide Score of 71 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.

Browse all stocks Congress tradesCongressional trading overviewNovartis AG ADR (NVS) stock overview

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.